Endo International plc. – Nasdaq: ENDP
Shares of Ireland-based Endo International plc. continue their 2017 slide. ENDP shares, traded on the Nasdaq, have lost around 1/3 of their value this year. Today Endo International settled allegations that Endo Pharmaceuticals violated antitrust law when it agreed to pay rivals Watson Laboratories and Impax to delay introducing generic versions of two painkillers. The FTC’s complaint, filed in the U.S. District Court for the Eastern District of Pennsylvania, alleged that certain aspects of the Opana® ER and Lidoderm® settlements constituted unfair methods of competition in violation of federal law and sought injunctive and declaratory relief, as well as other remedies including restitution and disgorgement.
Endo develops, manufactures, markets and distributes quality branded pharmaceutical and generic pharmaceutical products as well as over-the-counter medications through its operating companies worldwide.
Eighteen firms follow Endo International. Seven rate ENDP as a “Strong Buy”, one rates the shares a “Buy”, and ten rate ENDP as a “Hold”. The consensus price target is $20.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
|Last Price a/o 3:26 PM EST||$ 12.10|
|Average Volume||5.72 million|
|Market Cap||$2.8 Billion|
|Shares Outstanding||233 million|
|Share Float||221.48 million|
|Short Interest Ratio||2.43|